Adaptin Bio is a biotechnology company focused on developing precision cancer therapies with improved delivery to the brain and other tissues.
Charlotte, NC
Joined April 2025
- Tweets121
- Following60
- Followers16
- Likes3
This #HealthLiteracyMonth, we covered:
🧬 Tumor heterogeneity
🧠 Why surgery can't reach every cell
🚧 The blood-brain barrier
🚏 How BRiTE is designed to carry therapies
📖 Phase 1, decoded
🔗 How APTN-101 is designed to connect cells
Thanks for learning with us.
One end binds a marker on glioblastoma cells. The other binds T cells.
That's the idea behind APTN-101, Adaptin Bio's investigational bispecific T-cell engager: one molecule designed to connect an immune cell to a tumor cell.
You'll see "investigational" in a lot of biotech posts, including ours.
It means a therapy is being studied in clinical research and is not yet approved by regulators.
We're decoding the terms behind early clinical research. $APTN
Some therapies can't get into the brain on their own. So what if they caught a ride?
Adaptin Bio's investigational BRiTE platform is designed to use activated T cells to carry T-cell engagers across the blood-brain barrier.
$APTN
More than 95% of small-molecule drugs and more than 99% of large-molecule drugs do not cross the blood-brain barrier.
That delivery challenge is one of the questions shaping Adaptin Bio's investigational research.
#HealthLiteracyMonth $APTN
One tumor can contain cells with different target markers. That’s one aspect of tumor heterogeneity and a challenge shaping Adaptin’s research.
For #HealthLiteracyMonth, we’re explaining the science behind the strategy.
$APTN
Reaching the brain. Addressing differences among tumor cells.
Adaptin Bio President CEO Michael Roberts outlined how these two challenges shape Adaptin’s research into T-cell based delivery and modular tumor targeting.
$APTN
A preclinical study asked whether human regulatory T cells could be redirected toward glioblastoma cells with a bispecific antibody.
The study reported granzyme-dependent tumor-cell killing in the experimental setting.
Publication: bit.ly/4nbs9lr
$APTN
What will the APTN-101 Phase 1 study evaluate?
Primary objective: safety and maximum tolerated dose.
Secondary endpoints: pharmacokinetics and objective response rate.
Explore: bit.ly/4gmpBQ2
$APTN
On #WorldCancerResearchDay, Adaptin Bio recognizes the researchers, clinicians and study participants helping move new ideas forward.
Our focus is improving therapeutic delivery to the brain and other targeted tissues.
Learn more at: adaptinbio.com/
Why is delivering biologics to the brain so difficult?
Adaptin Bio CEO Michael Roberts and Duke neuro-oncologist Mustafa Khasraw discuss the challenge and the investigational BRiTE platform on Better Biopharma.
Watch to learn more: bit.ly/4rmYSru
$APTN
Today at 1:00 p.m. ET:
Adaptin Bio Co-Founder and CEO Michael Roberts presents at the Life Sciences Virtual Investor Forum hosted by @RIConferences.
Register to access the presentation: bit.ly/4yGQmWT $APTN
News from @DukeMedSchool features APTN-101, Adaptin Bio’s BRiTE immunotherapy being studied in a Phase I glioblastoma trial. The therapy is designed to cross the blood-brain barrier and direct T cells to EGFRvIII-expressing tumor cells.
Read: bit.ly/4j4Xesn $APTN
Adaptin Bio $APTN Co-Founder and CEO Michael Roberts will present at the Life Sciences Virtual Investor Forum hosted by @RIConferences on Thursday, September 17 at 1:00 p.m. ET.
Register to attend: bit.ly/4ivVFU9
Meet Kirit Singh, M.D., Ph.D., Chief Scientific Consultant at Adaptin Bio.
His work spans biomedical engineering, immunoengineering and translational research, including research supporting the APTN 101 program in glioblastoma.
Meet the team: bit.ly/3YSkKxY $APTN
Selecting a starting dose is a critical part of preparing an investigational therapy for first in human study.
Research in Adaptin Bio’s publication library examined the MABEL approach for an EGFRvIII x CD3 bispecific antibody.
Read more: bit.ly/3YSkKxY $APTN
Adaptin Bio’s Phase I trial of APTN-101 will evaluate safety, maximum tolerated dose, pharmacokinetics and objective response rate in adults with EGFRvIII positive glioblastoma. Read more on the study and Adaptin’s BRiTE platform via @TrialsArena. bit.ly/4xkdXwj $APTN
Glioblastoma tumors can differ in how they express EGFRvIII. Research underlying Adaptin Bio’s approach evaluated an EGFRvIII x CD3 bispecific antibody across patient derived malignant glioma models with varying levels of EGFRvIII expression. bit.ly/3YSkKxY $APTN
Adaptin Bio has opened enrollment in a Phase 1 clinical trial evaluating APTN-101 in patients with WHO Grade IV malignant glioma expressing EGFRvIII.
The first-in-human study is being conducted in collaboration with Duke University.
Learn more: bit.ly/4gmpBQ2 $APTN
Activated T cells can cross the blood brain barrier during immune surveillance.
Adaptin Bio’s BRiTE platform is built around that biology, with the goal of helping transport T cell targeting agents into the CNS.
Learn more: bit.ly/3YSkKxY $APTN
